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Abstract: Introduction
Malignant pleural mesothelioma (MPM) is an aggressive tumour strongly associated
with asbestos exposure. Patients are usually diagnosed when current treatments have
limited benefits, highlighting the need for non-invasive early diagnosis tests to monitor
asbestos-exposed people.
Methods
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
We used a genome-wide methylation array to identify, in asbestos-exposed subjects,
novel blood DNA methylation markers of MPM in 163 MPM cases and 137 cancer-free
controls (82/68 Training Set; replication in 81/69, Test Set) sampled from the same
areas.
Results
Evidence of differential methylation between MPM cases and controls was found (>800
CpG sites, Pfdr<0.05), mainly in immune system related genes.
Considering the “top” differentially methylated signals, 7 single-CpGs and 5 genomic
regions of coordinated methylation replicated with similar effect size in the Test Set
(pfdr<0.05).
The top hypomethylated single-CpG (cases vs controls effect size< 0.15, pfdr <0.05 in
both Training and Test sets) was detected in FOXK1 (Forkhead-box K1) gene, an
interactor of BAP1 which was found mutated in MPM tissue and as germline mutation
in familial MPM.
In the Test set, comparison of receiver operating characteristic (ROC) curves and the
area under the curve (AUC) of two models, including/excluding methylation, showed a
significant increase in case/control discrimination when considering DNA methylation
together with asbestos exposure (AUC=0.81 vs AUC=0.89, DeLong’s test p=0.0013).
Conclusions
We identified signatures of differential methylation in DNA from whole blood between
asbestos exposed MPM cases and controls. Our results provide the rationale to further
investigate, in prospective studies, the potential use of blood DNA methylation profiles
for the identification of early changes related to MPM carcinogenic process.
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Abstract 
 
Introduction 
Malignant pleural mesothelioma (MPM) is an aggressive tumour strongly associated with 
asbestos exposure. Patients are usually diagnosed when current treatments have limited 
benefits, highlighting the need for non-invasive early diagnosis tests to monitor asbestos-
exposed people. 
Methods 
We used a genome-wide methylation array to identify, in asbestos-exposed subjects, novel 
blood DNA methylation markers of MPM in 163 MPM cases and 137 cancer-free controls 
(82/68 Training Set; replication in 81/69, Test Set) sampled from the same areas. 
Results 
Evidence of differential methylation between MPM cases and controls was found (>800 CpG 
sites, Pfdr<0.05), mainly in immune system related genes. 
Considering the “top” differentially methylated signals, 7 single-CpGs and 5 genomic regions 
of coordinated methylation replicated with similar effect size in the Test Set (pfdr<0.05). 
The top hypomethylated single-CpG (cases vs controls effect size<-0.15, pfdr <0.05 in both 
Training and Test sets) was detected in FOXK1 (Forkhead-box K1) gene, an interactor of 
BAP1 which was found mutated in MPM tissue and as germline mutation in familial MPM. 
In the Test set, comparison of receiver operating characteristic (ROC) curves and the area 
under the curve (AUC) of two models, including/excluding methylation, showed a significant 
increase in case/control discrimination when considering DNA methylation together with 
asbestos exposure (AUC=0.81 vs AUC=0.89, DeLong’s test p=0.0013). 
Conclusions 
We identified signatures of differential methylation in DNA from whole blood between 
asbestos exposed MPM cases and controls. Our results provide the rationale to further 
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investigate, in prospective studies, the potential use of blood DNA methylation profiles  for 
the identification of early changes related to MPM carcinogenic process. 
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Keywords: Malignant Pleural Mesothelioma; DNA-methylation; case-control discrimination; 
asbestos exposure; early biomarker. 
 
Abbreviations 
MPM: Malignant Pleural Mesothelioma 
CpGs: cytosine-guanine dinucleotides 
DNAm: DNA methylation 
DMe: differential methylation 
DM-CpG: differentially methylated single CpG 
DMR: differentially methylated region 
WBCs: white blood cells 
FDR: false discovery rate 
PCs: principal components 
ROC curves: receiver operating characteristic curves 
AUC: area under the ROC curve 
EEAA: extrinsic epigenetic age acceleration 
IEAA: intrinsic epigenetic age acceleration 
EWAS: epigenome-wide association study 
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Introduction 
Malignant pleural mesothelioma (MPM) is an aggressive tumor strongly associated with 
asbestos exposure. It occurs long after the first exposure, with risk increasing depending on 
duration and intensity of exposure 1. MPM incidence dramatically increased as a result of 
widespread use of asbestos in the past decades. Banning occupational asbestos use and 
preventing environmental asbestos exposure is rewarded as the only effective strategy to 
hinder MPM occurrence. However, for subjects who underwent environmental or 
occupational asbestos exposure in the past there is no preventive measure currently available, 
except for continuous monitoring aiming at an early MPM diagnosis, that might improve life 
expectancy. Patients are in fact usually diagnosed in an advanced phase, where radical 
surgery cannot be carried out, and the effectiveness of current cytotoxic therapies is limited 2, 
highlighting an urgent need for sensitive non-invasive tests for early MPM diagnosis. 
In recent years, there is a growing interest in DNA methylation (DNAm) profile changes as 
possible diagnostic/prognostic biomarkers in cancer research 3.  
DNAm is stable, yet it may be modified across lifetime by several factors including lifestyle, 
environmental exposures, ageing, and diseases 4 and is thus rewarded as an adaptive 
phenomenon potentially linking environmental factors and development of disease 
phenotypes. Being an early event in tumor development, aberrant DNAm has been suggested 
as a tool for early cancer detection and prognosis 5, and DNAm changes are regarded as 
possible actors also in MPM development and progression 6. Along this line we sought 
whether white blood cells (WBCs) DNAm profiles might associate with MPM occurrence in 
subjects with asbestos exposure, considering that tumor environment in the pleura may 
trigger molecular changes in perfusing WBCs. 
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We thus investigated the occurrence of differences in the DNAm profiles in a large series of 
MPM cases and asbestos exposed controls, all of them with quantitative assessment of 
asbestos exposure. 
 
Materials and Methods 
Study population and asbestos exposure assessment 
Study subjects belong to a wider ongoing collaborative study on MPM already described in 
previous reports. 7-9 Details on study population are provided in Supplementary Methods. 
Briefly, cases and controls were enrolled either in the municipalities of Casale Monferrato 
(Piedmont region, Italy), an area with high occupational and environmental asbestos exposure, 
or Turin (Piedmont, Italy).  
Cases were enrolled in the main hospitals of the reference centers after histological 
confirmation of MPM diagnosis. Controls were randomly selected, from the local population 
(Casale Monferrato study) 7, 8, or among subjects not affected by neoplastic or respiratory 
conditions admitted to general medicine or urology units at the reference hospital (Turin 
study) 8.  
For all the subjects cumulative asbestos exposure was quantitatively assessed as described in 
Ferrante et al.10 Briefly, occupational history and lifestyle habits information was collected 
through interviewer-administered questionnaires filled out at enrolment during a face-to-face 
interview. An occupational epidemiologist assessed probability, frequency, intensity and 
duration of asbestos exposure (method detailed in in Ferrante et al. 10) for both occupational 
and non-occupational exposures, taking into account their occupational and residential 
history and other possible circumstances of asbestos exposure, like sharing home with an 
asbestos worker. 
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In total, 300 samples, 163 MPM cases and 137 non-MPM controls were included in this 
study underwent DNAm analysis. 
Our study complies with the Declaration of Helsinki principles, and conforms to ethical 
requirements. All volunteers signed an informed consent form at enrollment. The study 
protocol was approved by the Ethics Committee of the Italian Institute for Genomic Medicine 
(formerly Human Genetics Foundation, Turin, Italy). 
 
DNA-methylation analyses 
DNAm levels were measured in DNA from whole blood collected at subjects enrollment 
using the Infinium HumanMethylation450 BeadChip (Illumina) The percentage of 
methylation at each CpG site (methylation Beta-value), ranging from 0, no methylation, to 1, 
full methylation, was assessed for each subject. Laboratory methods for DNA extraction, 
BeadChip processing, methylation levels measurement, and data quality controls are detailed 
in Supplementary Methods. 
 
Statistical methods 
Study design is outlined in Supplementary Figure S1. 
All statistical analyses were conducted using the open source software Rv3.4.0 11. 
Subjects were randomly allocated (R function split) to two analytical sets: a Training set of 
82 MPM cases/68 controls (discovery panel), and a Test set of 81 cases/69 controls 
(replication panel). 
Possible differences between the two sets were checked for sex, age, center, exposure, tumor 
histotype, smoking habits, WBCs estimated percentages. The same comparison was done for 
descriptive purposes within each one of the two sets (Table 1). 
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Epigenome-wide differential methylation between cases and controls was tested by 
regression models described below both at single CpG and at “regional” level. For all the 
regression analyses, continuous variables such as age (years), and asbestos exposure doses 
(fibers/mL-years), were Rank transformed (R function rntransform) to remove skewness. 
WBC subtype percentages from genome-wide methylation data for each subject were 
estimated 12 to evaluate differences in WBCs profiles between cases and controls. However, 
since numeric changes and functional dysregulation of immunocompetent cells triggered by 
asbestos and linked to MPM ethiopathogenesis were reported in literature (Table 2), 
regression analyses were not adjusted by WBCs composition (see Discussion section). 
Potential population stratification was taken into account by including in the regression 
analyses the first two principal components (SNP_PCs1-2) calculated on the basis of our 
previous genome-wide genotyping study 9 (Supplementary Methods); batch and technical 
effects correction was performed adjusting for “BeadChip control probes” PCs1-10 
(CTR_Probes_PCs1-10; Suppl. Methods). Before inclusion as covariates into regression 
analyses, SNP_PCs1-2 and CTR_Probes_PCs1-10 variables were Rank transformed (R 
function rntransform). For multiple comparisons, Benjamini-Hochberg false discovery rate p 
(pfdr)≤0.05 was considered statistically significant. 
 
Single CpG analysis 
Cases-controls differential methylation (DMe) at Single-CpGs was tested in the Training set 
by generalized linear models analysis adjusted for asbestos exposure, gender, age, population 
stratification, and technical variability, as described above. 
Smoking habit was purposely not added to our multivariate statistical model since smoking is 
not among the known risk factors for mesothelioma. However, since smoking habits may 
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modify DNA methylation profiles at some genomic locations, its effect on methylation levels 
was targetedly investigated on CpGs differentially methylated between cases and controls. 
To ensure a power of the study greater than 90% (two-tailed test, 0.05 alpha error), only 
CpGs with regression effect sizes differences between cases and controls ≥|0.1| were 
considered in the discovery phase on the Training set, and subsequently investigated in the 
Test set under the same analytical conditions. CpGs with effect sizes differences between 
cases and controls ≥|0.1| and pfdr≤0.05 in both Training and Test sets were considered as 
replicating, and underwent gene set enrichment analysis (WEB-based GeneSeTAnaLysis 
Toolkit, WebGestalt; http://bioinfo.vanderbilt.edu/webgestalt). 
Additionally, Test set subjects were clustered (unsupervised clustering analysis, R package 
Rgplots) according to their methylation levels of the differentially methylated single-CpGs 
(DM-CpGs). For this analysis, samples with missing methylation Beta-values for any of the 
CpGs were removed. 
Finally, in the Test set, we compared the area under the receiver operating characteristic 
curve (AUC) of two models by the DeLong test : Model 1 included age, sex and asbestos 
exposure; Model 2 was as Model 1 plus methylation levels of significant and replicating 
DM-CpGs: this was done to test the potential improvement in case-control discrimination 
when considering DMe information together with asbestos exposure information. 
 
Regional differential methylation analysis 
We used the A-clustering algorithm to define genomic regions characterized by a group of 
two or more neighboring CpGs (CpGs clusters) with correlated methylation levels 
(Supplementary Methods) under the hypothesis that methylation changes in genomic regions 
may underlie potential functional changes linked to MPM. In the Training set, we tested the 
occurrence of differentially methylated regions (DMRs) between cases and controls by 
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generalized estimating equations with the same adjustments as the single-CpG analysis. 
DMRs with effect size differences of at least 0.1 between cases and controls were 
investigated for occurrence of DMe in the Test set under the same analytical conditions. 
DMRs replicating in the Test set (i.e. effect sizes ≥|0.1| and pfdr≤0.05 in both Training and 
Test sets) underwent gene set enrichment analysis. 
 
CpGs methylation vs gene expression 
Since our study envisaged the collection of DNA only, we were unable to assess RNA 
transcripts levels for our mesothelioma cases and related controls. To assess a possible 
relationship between differentially methylated CpGs and gene expression variations of the 
corresponding genes, we took advantage of other in-house studies for which whole 
transcriptome gene expression and DNAm data were available. Data from two sample sets 
were used: i) 72 healthy subjects included in a genotype-phenotype correlation study (from 
here on, Geno-Pheno) described elsewhere 13 for which methylation and gene expression 
were assessed on DNA and RNA from the same aliquot of peripheral blood mononuclear 
cells (PBMCs), and ii) 21 normal pleura surgical samples from donors that were subjected to 
thoracoscopy for conditions different from MPM, belonging to a previous study 8, for which 
whole genome methylation and whole transcriptome expression were recently assessed as a 
pilot study (data not shown). In the two studies, methylation levels were determined by the 
HumanMethylation450 BeadChip and quality controlled as described in Supplementary 
Methods. Gene expression levels were determined by the Illumina HumanHT-12 v4 
Expression BeadChip according to manufacturer’s instructions (Supplementary Methods). 
Genes were considered expressed if their probe(s) intensity signal(s) was(were) at least twice 
the BeadChip background. The relationship between methylation and transcript levels of 
genes was investigated with a Pearson’s correlation test. 
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DNA Methylation Age estimation and Age Acceleration Indices 
DNA Methylation age (DNAm-age) was estimated for each subject from DNAm levels on 
the overall sample according to the method proposed by Horvath et al. 14.  
Estimated DNAm-age was compared with chronological age by the Spearman correlation test. 
Age acceleration (AA) was calculated as the residuals of the DNAm-age estimate regressed 
on chronological age in both MPM cases and cancer-free controls: positive AA suggests a 
biological age “older” than chronological age, whilst a negative one suggests the individual is 
biologically “younger”. 
Two additional age acceleration indices, intrinsic epigenetic age acceleration (IEAA) and 
extrinsic epigenetic age acceleration (EEAA), were calculated as well. As reported by Chen 
et al. 14, EEAA is influenced by blood cell count contribution, whereas IEAA value is only 
weakly correlated with estimated measures of blood cell counts. The two indices, estimated 
from DNAm data, are thus indicators of 2 different cellular ageing processes, one (EEAA) 
dependent on and the other (IEAA) independent from WBC count. Differences between cases 
and controls were tested by W test with p ≤0.05 considered statistically significant, and by a 
generalized linear models analysis adjusted for sex and asbestos exposure levels. 
 
Results 
Sample descriptive statistics are reported in Table 1. 
The distribution of subjects’ characteristics of cases and controls included in the Training set 
and cases and controls included in Test set is rather homogeneous and comparable: Training 
and Test set subjects did not differ by age, tumor histology, smoking habits, exposure dose 
and source, estimated WBCs percentages (W test), sex, center of recruitment, case-control 
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distribution (Chi-square Test), except for a difference in B cells distribution in controls 
between Training set and Test set (W test, p=0.04). 
Conversely, when comparing cases vs. controls within each of the 2 sets, cases were exposed 
to significantly higher cumulative doses of asbestos than controls, and had statistically 
significant differences in WBCs distribution with respect to controls (Table 1). 
After quality controls on raw DNAm data, 389,147 CpG were used in the following analyses. 
 
Single-CpGs differential methylation analysis 
In the Training set, 887 CpGs had effect size ≥ǀ0.10ǀ at case-control DMe analysis, 884 of 
them with pfdr<0.05. Thirteen CpGs were hypermethed in cases, while 871 were 
hypomethylated (Supplementary Table S1). Out of the 884 significantly differentially 
methylated CpGs in the Training set, 868 showed significant DMe (pfdr targeted<0.05) also in 
the Test set with concordant and similar effect sizes (Supplementary Table S1), and were 
annotated to 599 genes that were analyzed for pathway enrichment. We found statistically 
significant enrichment for Neutrophil Degranulation, Innate Immune System and Immune 
System (Supplementary Table S2-A). 
Appraised the huge number of hypomethylated signals (N=871) identified in the Training set, 
we posed a more stringent threshold at effect size ≤-0.15, obtaining a smaller group of 20 
hypomethylated CpGs. The resulting DM-CpGs list from the discovery analysis in the 
Training set, thus, included 20 hypomethylated CpGs with effect size ≤-0.15 and 13 
hypermethylated with effect size ≥0.10. Checking for strictly replicating signals in the Test 
set, we ended up with 7 “top DM-CpGs”, 3 hypomethylated CpGs with effect sizes ≤-0.15 in 
both Training and Test sets (genes FOXK1, MYB, and TAF4) and 4 CpGs hypermethylated 
with effect sizes ≥0.10 in both Training and Test sets (genes CXCR6/FYCO1, TAP1, MORC2, 
LIME1) (Table 3). 
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We then performed two unsupervised clustering analyses on Test set samples to inspect the 
distribution of cases and controls according to their methylation levels at the DM-CpGs 
identified in the Training set: the first one (Supplementary Fig. S2-A) included the top 
DM-CpGs, irrespective of strict replication criteria, i.e. all the 33 top DM-CpGs, identified in 
the Training set; the second one (Supplementary Fig. S2-B) included only the 7 DM-CpGs 
whose effect sizes strictly replicated in the Test set, as described above. Cutting the sample 
dendrograms at the first node, in both analyses the groups with the most 
hypomethylated/hypermethylated DM-CpGs included the highest proportion of cases as 
compared to the other group (Supplementary Fig. S2-A,B). 
The AUC comparison of 2 models (see methods) showed a statistically significant 
improvement in discrimination between cases and controls when including methylation levels 
into the analysis (Figure 1). 
A univariate regression analysis in the overall MPM cases (N=163) was done to check for a 
possible relationship between methylation levels at each of the 7 DM-CpGs vs. tumor 
histotype, coded as epithelioid, sarcomatoid/fibrous, biphasic/mixed, non-defined, and 
unknown. Taking “epithelioid” histotype as the reference one, no clear evidence of 
methylation differences linked to different histotypes was found, except for the methylation 
levels of cg08450017 in CXCR6/FYCO1, that were significantly slightly reduced in 
biphasic/mixed MPMs with respect to epithelioid type (effect size±s.e.=-0.05±0.03, p=0.048). 
To assess if smoking habits could modify DNA methylation profiles at the 7 DM-CpGs, we 
categorized all subjects as current- former- and never-smokers, and then performed a 
multivariate regression analysis in the overall sample (163 MPM cases,137 controls) with the 
same model used for the “discovery phase” adding also smoking status as covariate. No 
evidence of methylation differences linked to different smoking categories was found for any 
of the “top” CpGs, except for the methylation levels of cg00446123 in LIME1, that were 
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significantly slightly reduced in ex-smokers with respect to current smokers taken as the 
reference group (effect size±s.e.=-0.034±0.017, p=0.049). 
For a subset of cases, for which more detailed clinical information was available, we checked 
for a possible relationship between methylation levels of the “top” 7 CpGs and time of blood 
drawing, and cTNM. Results are reported in Supplementary File (Supplementary Results). 
Lastly, the possible relationship between methylation levels and genomic variability was 
checked for FOXK1, that  is located in region 7p22.2 which was found associated with MPM 
in our previous GWAS report 9 and in the companion paper of our collaborators 15. Results 
are reported in Supplementary File (Supplementary Results). 
 
Regional differential methylation analysis 
The A-clustering algorithm identified 24,573 CpGs clusters with correlated methylation 
levels in the Training set and 23,676 in the Test set, that were tested for differential 
methylation between cases and controls. As a first step, we checked for clusters of 
differentially methylated CpGs around the 7 “top DM-CpGs” identified at the single-CpGs 
analysis, and found that 5 out of the 7 top DM-CpGs identified at the single CpGs analysis 
were indeed included in CpGs clusters differentially methylated between cases and controls 
(Table 4). 
As a second step, across the 24,573 CpGs clusters identified in the Training set, we looked 
for DMRs between cases and controls with effect size ≥ǀ0.10ǀ, and found 35 DMRs 
hypomethylated (pfdr<0.05) in Training set cases. Among the 35 regions, the broadest cluster 
included 9 CpGs in FOXK1 gene around cg04572930, that was the most hypomethylated 
CpG identified at single-CpG analysis. No region was hypermethylated above the established 
threshold (effect size ≥ǀ0.10ǀ) in cases with respect to controls in the Training set. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
16/27 
 
All the 35 regions identified in the Training set were represented as clusters also in the Test 
set, and all of them showed statistically significant hypomethylation in cases 
(range[-0.12;-0.07], median=-0.10, pfdr<0.05) (Supplementary Table S3). Restricting the 
analysis to clusters with effect size ≤-0.10 and pfdr<0.05 in both Training and Test sets (i.e. 
strictly replicating DMRs), 21 regions corresponding to 21 genes were identified. The 5 
regions with more than 2 CpGs in cluster were noted as “top DMRs”, and corresponded to 
the following genes: FOXK1 (9 CpGs), CSTA (4 CpGs), ZNF516 (3 CpGs), TOLLIP (3 
CpGs), TNFAIP6 (3 CpGs). 
At a gene-set analysis on the 21 DMRs, no statistically significant enriched category rwas 
found. However, considering enriched categories that included more than 1 gene, we found 
the most represented pathways were related to immune systems processes (3 categories, 5 
genes in multiple categories), cancer related pathways (5 categories, 7 genes in multiple 
categories), and developmental biology (1 category, 5 genes) (Supplementary Table S2-B). 
 
CpGs methylation vs Gene expression 
The methylation levels of the 7 differentially methylated single-CpGs and of the 21 CpGs 
from the regional analysis were correlated with the corresponding gene-expression levels in 2 
separate datasets: one comprising methylation and gene expression data from healthy subjects 
(Geno-Pheno) PBMCs’, and the other one comprising methylation and gene expression data 
from healthy pleura. 
In the Geno-Pheno dataset we found no significant correlation between methylation levels 
and transcript levels in PBMCs for any of the considered CpGs. 
In the healthy pleura dataset, cg08450017 in FYCO1, and 8 out of 9 CpGs in the FOXK1 
cluster showed a statistical significant correlation between methylation levels and the 
corresponding gene transcript levels (Table 5). 
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DNA Methylation Age and Age Acceleration 
DNAm-age was estimated for each subject from methylation levels in blood cells, and 
showed a strong correlation with chronological age (Spearman’s rank correlation rho=0.80, 
p<2.2E-16). 
AA index did not significantly differ between cases and controls: Wilcoxon rank sum test, 
residuals median[interquartile range], AAcases=176.0[97.5;256.0], AAcontrols=168[65.0;261.0], 
Wilcoxon p=0.50; GLM analysis, effect size(se)= -2.24(12.81), p=0.86. 
Considering the additional AA indices estimated on the overall sample, IEAA, which 
accounts for WBCs composition, did not significantly differ between cases and controls: 
median[interquartile range], IEAAcases=0.22[-3.17;3.37], IEAAcontrols=0.06[-3.82;2.80], 
Wilcoxon p=0.49, GLM effect size(se)= 0.74(0.68), p=0.28. 
On the other hand, EEAA, which does not account for WBCs composition, was significantly 
different between cases and controls: EEAAcases=0.51[-3.35;5.75], 
EEAAcontrols=-0.42[-5.04;2.57], Wilcoxon p=0.007,  LM effect size(se)= 2.27(0.86), p=0.009. 
 
Discussion 
Altered DNA methylation is frequently observed in cancer, and DNAm profiles of specific 
genes were already proposed as potential tools for cancer detection, risk prediction, and 
prognosis 5. In our study we investigated WBCs DNAm profiles in a large series of MPM 
cases and controls, all of them with quantitative assessment of asbestos exposure, with the 
aim of identifying molecular hallmarks of MPM in non-invasively collected blood samples 
from asbestos-exposed subjects. The role of the immune system in cancer is well known , 
including mesothelioma 16, and there are evidences that asbestos related antigenic 
overstimulation and ROS oxidation trigger functional changes in WBCs 17. Moreover, several 
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previous reports, summarized in Table 2, suggest asbestos-induced immune system 
deregulation, autoimmune response and functional changes in WBCs, putatively linked to 
MPM occurrence. 
Indeed, the reduction of estimated CD4+ and CD8+ T lymphocytes in MPM cases, that we 
observed in our study, suggests a weaker adaptive immune system, and is compatible with the 
possible occurrence of functional changes in cellular subpopulations in MPM 18. 
Considering these evidences, we hypothesized that both numerical and functional changes in 
WBCs might be reflected in methylation changes in MPM cases compared with controls, thus 
we did not include WBC estimated counts as covariate in our analyses. In general, WBCs 
model adjustment is meant to control for inter-individual variability, which might be essential 
when healthy subjects are compared, but might introduce biases when analyzing subjects 
with diseases that trigger immune system response resulting in different cell counts and 
activation profiles. 
In our sample MPM cases showed “older” WBCs than controls according to epigenetic 
ageing profiles: the EEAA index 14, which does not account for differences in WBCs 
compositions, is significantly different between cases and controls, indicating that cases’ 
WBCs are epigenetically older than those of controls. Epigenetic age acceleration was 
associated with mortality and age-related diseases 19-21, and may play a role in MPM too, 
making it worthy of further investigation. 
In this study we identified signals of cases-controls differential DNAm both at single-CpG 
and regional analyses. The “top” hypomethylated DM-CpG is located in FOXK1 (Forkhead 
Box K1), a transcription factor involved in development and metabolism, and Wnt signaling22. 
We found FOXK1 differentially methylated also at regional analysis, with a 9 CpGs cluster 
hypomethylated in cases. The involvement of FOXK1 in tumor onset and progression was 
previously reported for colorectal and gastric cancers 23, 24. It was also recently reported that 
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mTORC mediated de-phosphorylation of FOXK1 transactivates CCL2 gene promoting tumor 
associated macrophages infiltration in mice, contributing to tumor progression. 25  
Moreover, FOXK1 directly interacts with BAP1 (BRCA1-associated protein 1) 26, whose 
involvement in MPM has been already described 27-29. 
Notably, FOXK1 is located on chromosome 7p22.2, one of the 5 genomic regions that we 
previously identified as associated to MPM in a GWAS on Italian samples and that were 
further replicated in an independent Australian MPM sample 9. However, no evident 
relationship between methylation levels and genomic variation at FOXK1 locus was found, at 
least for the 6 SNPs for which the genotypes were available in our sample (Supplementary 
File, Supplementary Results).  
The most hypermethylated single-CpG signal is located in FYCO1 (FYVE And Coiled-Coil 
Domain Containing 1) gene body, and in the promoter region of CXCR6 (C-X-C Motif 
Chemokine Receptor 6) gene, which is antisense transcribed to FYCO1 intron 14. 
Interestingly enough, FYCO1 encodes for a putative FOXK1 interactor within the human 
autophagy network 30. In the present study, CpGs in FYCO1 and FOXK1 are the only signals 
whose methylation levels showed significant positive correlation with gene expression levels, 
as measured in a set of healthy pleura samples. 
CXCR6, a T cell chemokine receptor, and its ligand, the chemokine CXCL16, were recently 
described as markers and promoters of inflammation-associated cancers, such as prostate 
cancer, and were suggested as mediators of inflammation-related tumorigenesis through 
direct effects on cancer cell growth and by inducing the migration and proliferation of tumor-
associated leukocytes 31.The same authors reported that the expression of CXCR6/CXCL16 
in both cancer cells and adjacent T cells correlated with prostate cancer progression. 
Out of the 868 DM-CpGs (599 genes) and the 21 DMRs (21 genes), we found several signals 
in genes belonging to “Neutrophil Degranulation”, “Innate Immune System”, and “Immune 
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System” Reactome pathways. This is not surprising, since we are studying DNAm in WBCs 
with the purpose to identify relevant changes potentially associated with processes leading to 
MPM onset. 
Among the “top signals”, three out of the 5 hypermethylated DM-CpG i.e. TAP1 (Transporter 
1, ATP Binding Cassette Subfamily B Member), LIME1 (Lck Interacting Transmembrane 
Adaptor 1) and CXCR6 (C-X-C Motif Chemokine Receptor 6), as well as 3 of the top DMRs, 
i.e. CSTA (Cystatin A), TOLLIP (Toll Interacting Protein) and TNFAIP6 (TNF Alpha 
Induced Protein 6) have a role in the immune system and/or inflammation-related processes. 
32-35. 
Taken together, our findings of DMe in WBCs suggest that DNAm changes in the immune 
system components may play a role in or may be a consequence of the oncogenic process 
triggered by asbestos exposure. However, a major limitation to the functional interpretation 
of our results is that all MPM subjects have already developed the disease at recruitment: thus, 
our findings likely reflect the disease status rather than being causal factors in the dynamic 
processes leading to MPM onset. Cases were enrolled at MPM diagnosis, when the tumor 
was already in place, so we cannot exclude a “reverse causality” bias, and we are thus unable 
to establish whether methylation changes are associated with the carcinogenic process, or are 
consequence of the disease.  
Another limitation is the unavailability of MPM tissue from the same subjects, that also poses 
major constrains to the functional interpretation of our findings and prevents the possibility to 
compare DNAm profiles in blood cells and in tissue samples or pleural effusions of MPM 
cases. Even though we could not prove, in the context of this study, whether or not DNA 
methylation profiles in blood reflect the status of the tumor, in our view they may be assumed 
as “biomarkers” of actual disease (given the cross-sectional nature of the study). As a matter 
of fact, notwithstanding the above limitations, the discrimination between MPM cases and 
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non-MPM asbestos exposed controls improved when DNAm levels were taken into account 
together with asbestos exposure levels. 
The significant difference in degree of asbestos exposure between case and control is a 
critical issue in verifying these signatures as markers for the early detection of MPM in 
asbestos-exposed subjects. For this reason, we corrected our analyses for individual levels of 
asbestos exposure, taking advantage of well recorded asbestos exposure information, and thus 
we identified DNA methylation biomarkers which are not directly associated to asbestos 
exposure. Since it is not always possible to accurately quantify asbestos doses for exposed 
subjects; it is important to develop tools to confidently identify those asbestos exposed 
subjects who are prone to MPM occurrence also when it is not possible to assess the 
cumulative dose they have been exposed to. The here reported evidences of detectable 
methylation differences in asbestos exposed subjects with and without MPM provide the 
rationale to search for possible DNA methylation early changes associated to MPM 
development. Monitoring methylation changes on the trajectory to the disease, from asbestos 
exposure to overt MPM diagnosis, is a necessary task for the identification of early epigenetic 
changes biomarkers related to MPM to be employed for the monitoring of asbestos-exposed 
subjects. MPM is characterized by the accumulation and persistence of asbestos fibers in the 
lungs, leading to a long latency period before clear clinical signs of the tumor are detectable. 
As of today, early MPM detection is still poor. Serum biomarkers such as Mesothelin, 
megakaryocyte potentiating factors, Osteopontin, CYFRA21-1, and Fibulin-3 were tested for 
early MPM diagnosis with limited results 36 and, so far, neither radiologic nor biochemical 
screening studies have proven useful. In our view, progressive changes in WBCs’ DNA 
methylation levels might thus provide a tool to monitor progressive alterations in the immune 
system of asbestos exposed subjects, potentially related to MPM development (Figure 2). 
Further studies in prospectively collected cohorts of asbestos-exposed subjects with blood 
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sampling at multiple points across time will be needed to clarify if, and to what extent, 
methylation changes progress across time towards the tumor onset. This is particularly 
important since, despite the banishment of asbestos itself and asbestos-containing materials in 
several countries, individuals who have already been exposed will remain at risk of MPM, 
whose incidence is just expected to peak in the next years in European countries. 
Overall, our study identified signatures of differential methylation in DNA from whole blood 
between asbestos exposed MPM cases and non-MPM controls, both at single-CpGs and at 
genomic region levels. We suggest that differential methylation patterns of selected CpGs in 
DNA from WBCs may aid in discriminating MPM cases from asbestos-exposed non MPM 
subjects and can be used to further improve MPM risk estimation is subjects occupationally 
and/or environmentally exposed to asbestos. 
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Figure1 legend 
Figure 1: Receiver Operating Characteristic (ROC) curves on Test set 
Model 1 (dotted line): age, sex, asbestos exposure levels 
Model 2 (solid line): age, sex, asbestos exposure levels, CpGs methylation levels 
 
Figure 2: hypotheses generation and rationale for future studies following the identification 
of differential methylation between asbestos exposed subjects with and without MPM. 
 
 
 
Additional Material 
Supplementary File.docx: Supplementary File 
Supplementary Figure S1.pdf: Study design outline 
Supplementary Figure S2.pdf: Clustering Analysis 
Supplementary Table S1.pdf: Single-CpGs differential methylation analysis tables 
Supplementary Table S1.docx: WebGestalt REACTOME enrichment 
Supplementary Table S3.docx : Differentially methylated CpGs clusters (A-clustering 
regional analysis)  
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
24/27 
 
Acknowledgements 
We wish to thank all the volunteers who participated in the project, making this study 
possible. 
We would also like to thank Prof. S. Horvath (Department of Human Genetics, UCLA 
School of Medicine, Los Angeles, CA, USA) for his valuable help in Methylation Age 
analyses and for fruitful discussion. 
 
Ethics statement 
Our study complies with the Declaration of Helsinki principles, and conforms to ethical 
requirements. All volunteers signed an informed consent form at enrollment. The study 
protocol was approved by the Ethics Committee of the Italian Institute for Genomic Medicine 
(formerly Human Genetics Foundation, Turin, Italy). 
 
Authors’ contribution 
GM, CM, ID, DM, SG, CV, GC conceived and designed the study 
CM, DF, DM enrolled the subjects, organized the case-control study, managed personal 
information databases 
CC, FG, RL, EP provided the MPM samples and data 
DM developed the exposure assessment protocol and evaluated exposure levels for all the 
subjects 
SG, AAllione, EC carried out the laboratory analyses 
CV, GC carried out the statistical analyses 
SG, AAllione, CV, EC substantially contributed to the interpretation of results 
SG wrote the manuscript 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
25/27 
 
GM, DM, CM, ID, MB, DF, AAspesi critically revised the manuscript and provided 
important intellectual content 
All authors read and approved the final manuscript 
 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
26/27 
 
References 
1. Magnani C, Bianchi C, Chellini E, et al. III Italian Consensus Conference on Malignant 
Mesothelioma of the Pleura. Epidemiology, Public Health and Occupational Medicine related issues. 
Med Lav 2015;106:325-332. 
2. Nowak AK. Chemotherapy for malignant pleural mesothelioma: a review of current 
management and a look to the future. Ann Cardiothorac Surg 2012;1:508-515. 
3. Dong Y, Zhao H, Li H, et al. DNA methylation as an early diagnostic marker of cancer (Review). 
Biomed Rep 2014;2:326-330. 
4. Kanherkar RR, Bhatia-Dey N, Csoka AB. Epigenetics across the human lifespan. Front Cell Dev 
Biol 2014;2:49. 
5. Shivapurkar N, Gazdar AF. DNA methylation based biomarkers in non-invasive cancer 
screening. Curr Mol Med 2010;10:123-132. 
6. Vandermeers F, Neelature Sriramareddy S, Costa C, et al. The role of epigenetics in 
malignant pleural mesothelioma. Lung Cancer 2013;81:311-318. 
7. Dianzani I, Gibello L, Biava A, et al. Polymorphisms in DNA repair genes as risk factors for 
asbestos-related malignant mesothelioma in a general population study. Mutat Res 2006;599:124-
134. 
8. Betti M, Ferrante D, Padoan M, et al. XRCC1 and ERCC1 variants modify malignant 
mesothelioma risk: a case-control study. Mutat Res 2011;708:11-20. 
9. Matullo G, Guarrera S, Betti M, et al. Genetic variants associated with increased risk of 
malignant pleural mesothelioma: a genome-wide association study. PLoS One 2013;8:e61253. 
10. Ferrante D, Mirabelli D, Tunesi S, et al. Pleural mesothelioma and occupational and non-
occupational asbestos exposure: a case-control study with quantitative risk assessment. Occup 
Environ Med 2016;73:147-153. 
11. R-CoreTeam. R: A language and environment for statistical computing. R Foundation for 
Statistical Computing. Available at Vienna, Austria, 2014  http://www.R-project.org/.  
12. Horvath S, Levine AJ. HIV-1 Infection Accelerates Age According to the Epigenetic Clock. J 
Infect Dis 2015;212:1563-1573. 
13. Allione A, Guarrera S, Russo A, et al. Inter-individual variation in nucleotide excision repair 
pathway is modulated by non-synonymous polymorphisms in ERCC4 and MBD4 genes. Mutat Res 
2013;751-752:49-54. 
14. Chen BH, Marioni RE, Colicino E, et al. DNA methylation-based measures of biological age: 
meta-analysis predicting time to death. Aging (Albany NY) 2016;8:1844-1865. 
15. Cadby G, Mukherjee S, Musk AW, et al. A genome-wide association study for malignant 
mesothelioma risk. Lung Cancer 2013;82:1-8. 
16. Nishimura Y, Kumagai-Takei N, Matsuzaki H, et al. Functional Alteration of Natural Killer Cells 
and Cytotoxic T Lymphocytes upon Asbestos Exposure and in Malignant Mesothelioma Patients. 
Biomed Res Int 2015;2015:238431. 
17. Maeda M, Nishimura Y, Kumagai N, et al. Dysregulation of the immune system caused by 
silica and asbestos. J Immunotoxicol 2010;7:268-278. 
18. Miura Y, Nishimura Y, Katsuyama H, et al. Involvement of IL-10 and Bcl-2 in resistance 
against an asbestos-induced apoptosis of T cells. Apoptosis 2006;11:1825-1835. 
19. Perna L, Zhang Y, Mons U, et al. Epigenetic age acceleration predicts cancer, cardiovascular, 
and all-cause mortality in a German case cohort. Clin Epigenetics 2016;8:64. 
20. Levine ME, Hosgood HD, Chen B, et al. DNA methylation age of blood predicts future onset 
of lung cancer in the women's health initiative. Aging (Albany NY) 2015;7:690-700. 
21. Zheng Y, Joyce BT, Colicino E, et al. Blood Epigenetic Age may Predict Cancer Incidence and 
Mortality. EBioMedicine 2016;5:68-73. 
22. Wang W, Li X, Lee M, et al. FOXKs promote Wnt/beta-catenin signaling by translocating DVL 
into the nucleus. Dev Cell 2015;32:707-718. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
27/27 
 
23. Wu M, Wang J, Tang W, et al. FOXK1 interaction with FHL2 promotes proliferation, invasion 
and metastasis in colorectal cancer. Oncogenesis 2016;5:e271. 
24. Peng Y, Zhang P, Huang X, et al. Direct regulation of FOXK1 by C-jun promotes proliferation, 
invasion and metastasis in gastric cancer cells. Cell Death Dis 2016;7:e2480. 
25. Nakatsumi H, Matsumoto M, Nakayama KI. Noncanonical Pathway for Regulation of CCL2 
Expression by an mTORC1-FOXK1 Axis Promotes Recruitment of Tumor-Associated Macrophages. 
Cell Rep 2017;21:2471-2486. 
26. Yu H, Mashtalir N, Daou S, et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary 
complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol 
2010;30:5071-5085. 
27. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant 
mesothelioma. Nature genetics 2011;43:1022-1025. 
28. Betti M, Aspesi A, Biasi A, et al. CDKN2A and BAP1 germline mutations predispose to 
melanoma and mesothelioma. Cancer Lett 2016;378:120-130. 
29. Betti M, Casalone E, Ferrante D, et al. Inference on germline BAP1 mutations and asbestos 
exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. Genes, 
chromosomes & cancer 2015;54:51-62. 
30. Behrends C, Sowa ME, Gygi SP, et al. Network organization of the human autophagy system. 
Nature 2010;466:68-76. 
31. Darash-Yahana M, Gillespie JW, Hewitt SM, et al. The chemokine CXCL16 and its receptor, 
CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One 2009;4:e6695. 
32. Leone P, Shin EC, Perosa F, et al. MHC class I antigen processing and presenting machinery: 
organization, function, and defects in tumor cells. J Natl Cancer Inst 2013;105:1172-1187. 
33. Keppler D. Towards novel anti-cancer strategies based on cystatin function. Cancer Lett 
2006;235:159-176. 
34. Kim H, Phung Y, Ho M. Changes in global gene expression associated with 3D structure of 
tumors: an ex vivo matrix-free mesothelioma spheroid model. PLoS One 2012;7:e39556. 
35. Qi F, Okimoto G, Jube S, et al. Continuous exposure to chrysotile asbestos can cause 
transformation of human mesothelial cells via HMGB1 and TNF-alpha signaling. Am J Pathol 
2013;183:1654-1666. 
36. Wolff H, Vehmas T, Oksa P, et al. Asbestos, asbestosis, and cancer, the Helsinki criteria for 
diagnosis and attribution 2014: recommendations. Scand J Work Environ Health 2015;41:5-15. 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Table 1: Sample characteristics and descriptive 
 
TRAINING SET  
 
 TEST SET  
 
 
Cases (N=82) Controls (N=68) p a   Cases (N=81) Controls (N=69) p a 
    
 
  
 
 
Casale M. [N (%)] 51 (62.20) 51 (75.00)  
ns 
 49 (60.49) 43 (62.32)  
ns 
Torino [N (%)] 31 (37.80) 17 (25.00)   32 (39.51) 26 (37.68)  
     
 
    
Males [N (%)] 60 (73.17) 43 (63.24)  
ns 
 53 (65.43) 57 (82.61)  
0.03 
Females [N (%)] 22 (26.83) 25 (36.76)   28 (34.57) 12 (17.39)  
Age [years, mean±sd] 68.46±11.41 65.16±10.07 
 
0.02 
 
66.71±10.67 64.02±10.00 
 
ns 
Exposure dose [mean±sd]b 34.8±165.39 5.11±12.46 
 
2.4 x 10-6 
 
62.98±194.51 2.13±3.43 
 
1.5 x 10-8 
Exposure source          
    Occupational [N (%)] 52 (63.41) 39 (57.35)    54 (66.67) 32 (46.38)   
    Domestic [N (%)]c 13 (15.85)   8 (11.76)  ns  12 (14.81)   7 (10.14)  0.004 
    Environmental [N (%)] 17 (20.73) 21 (30.88)    15 (18.52) 30 (43.48)   
Smoking habits          
    Current smokers [N (%)] 18 (21.95) 13 (19.12)     11 (13.58) 17 (24.64)   
    Former smokers [N (%)] 30 (36.59) 29 (42.65)  ns  24 (29.63) 31 (44.93)   
    Never smokers [N (%)] 34 (41.46) 26 (38.24)    41 (50.62) 21 (30.43)  0.02 
    N/A - -    5 (6.17) -   
Histologic Subtype          
    Epithelioid [N (%)] 54 (65.85)     55 (67.90)    
    Sarcomatoid [N (%)] 10 (12.20)     6 (7.41)    
    Biphasic [N (%)] 12 (14.63)     16 (19.75)    
    Undefined [N (%)] 1 (1.22)     2 (2.47)    
    Not known [N (%)] 5 (6.10)     2 (2.47)    
Estimated WBCs percentages d         
CD8T % [mean±sd] 0.03±0.05 0.06±0.05  6.3 x 10-5  0.03±0.03 0.07±0.04  4.0 x 10-10 
CD4T % [mean±sd] 0.07±0.05 0.15±0.07  2.2 x 10-10  0.08±0.05 0.14±0.06  2.3 x 10-7 
NK % [mean±sd] 0.05±0.05 0.08±0.05  1.3 x 10-3  0.06±0.04 0.07±0.05  0.04 
Table 1
B cells % [mean±sd] 0.06±0.02 0.09±0.03  4.1 x 10-10  0.06±0.03 0.08±0.03  5.0 x 10-5 
Monocytes % [mean±sd] 0.07±0.04 0.07±0.04  ns  0.08±0.05 0.07±0.03  0.01 
Granulocytes % [mean±sd] 0.74±0.13 0.61±0.11  2.0 x 10-10  0.73±0.11 0.62±0.11  2.6 x 10-8 
 
a Chi-square test (two-sided, 2X2 contingency table) for Centre, Sex, Exposure source, and Smoking habits; Wilcoxon Rank Sum test (two-sided, 
Cases vs Controls) for Age, Exposure, WBC estimated percentages. Statistically significant when p≤0.05 
b fibers/mL year 
c Sharing house with an asbestos worker, or having asbestos-containing tools/materials in the house 
d Percentages estimated from methylation data for all WBCs 
 
Table 2: Reports of asbestos-induced potential immune system deregulation 
Observation References 
 asbestos exposure is associated with autoimmune response 
 possible relationship between immunological pathways and processes leading to asbestos-
related diseases 
 asbestos and asbestos-related inflammation may modify cellular and molecular features of 
immunocompetent cells eventually leading to reduction of tumor immunity 
Pfau JC, et al, Environmental health perspectives. 
2005; 113: 25-30 
Noonan CW, et al, Environmental health 
perspectives. 2006; 114: 1243-7 
Matsuzaki, H., et al, Journal of biomedicine & 
biotechnology, 2012. 2012: p. 492608 
 significant reduction in surface expression levels of NK-cell specific activating receptors in 
NK cell line YT-A1 exposed to chrysotile asbestos 
 reduction of the intracellular serine protease granzyme A secreted by NK cells against 
tumor cells 
 reduction of degranulation events 
Nishimura Y, et al, International journal of 
immunopathology and pharmacology. 2009; 22: 
579-90 
Nishimura, Y., et al, Biomed Res Int, 2015. 2015: 
p. 238431 
Maeda M, et al, Journal of immunotoxicology. 
2010; 7: 268-78 
 MT-2 cells (human T-lymphocyte immortalized polyclonal T-lymphocyte line) exposed to 
short-term high dose of chrysotile asbestos showed apoptosis, ROS production, activation of 
the mitochondrial apoptotic pathway, similarly to what found in alveolar epithelial and 
pleural mesothelial cells exposed in vitro to asbestos 
 long-term low-dose exposure of the same cell line showed resistance to asbestos, long term 
survival, and T-lymphocyte Vβ receptors activation, suggesting an asbestos-related super-
antigenic activity in human T-lymphocytes 
Maeda M, et al, Journal of immunotoxicology. 
2010; 7: 268-78 
Miura Y, et al, Apoptosis : an international journal 
on programmed cell death. 2006; 11: 1825-35 
Table 2
 a particular fraction of CD4+ T lymphocytes acquires apoptosis resistance through 
activation of STAT3 and transcriptional activation of bcl-2, after direct interaction with 
asbestos fibers 
 CD4+ T lymphocytes from asbestosis patients without signs of a malignant tumor showed 
relative expression of bcl-2 similar to that of healthy donors 
 CD4+ T lymphocytes from malignant mesothelioma patients exhibited significant up-
regulation of bcl-2 expression, suggesting the onset of MPM might be related to the 
enhanced survival of a specific population of CD4+T lymphocytes 
Miura Y, et al, Apoptosis : an international journal 
on programmed cell death. 2006; 11: 1825-35 
 
 
Table 3: Differentially methylated CpGs in the Training set and Test set 
List of the top CpGs hypomethylated with effect size ≤-0.15 and hypermethylated with effect size ≥0.10 in both Training set and Test set (cases vs 
controls) 
 
     
TRAINING-SET   TEST-SET 
Probe ID Chr Map position 
(GRCh37/hg19) 
Gene 
Symbol 
UCSC 
Refgene 
Group 
Beta-values 
Eff. size±se p p fdr EWAS 
 
Beta-values 
Eff. size±se p p fdr EWAS 
 
Cases Controls 
 
Cases Controls 
p fdr 
TARGETED 
 
Mean±sd Mean±sd  Mean±sd Mean±sd  
CpGs hypomethylated in MPM cases 
      
 
     
 
cg04572930 7 4754834 FOXK1 Body 0.35±0.17 0.54±0.16 -0.18±0.03 5.19E-08 2.46E-05  0.37±0.19 0.51±0.16 -0.17±0.03 1.19E-06 1.75E-04 2.93E-06 
cg04739200 6 135517046 MYB Body 0.32±0.14 0.48±0.15 -0.16±0.03 5.94E-08 2.64E-05  0.30±0.14 0.48±0.17 -0.16±0.03 5.56E-07 1.05E-04 1.62E-06 
cg01521397 20 60590872 TAF4 Body 0.33±0.16 0.50±0.16 -0.16±0.03 5.18E-07 8.58E-05  0.35±0.15 0.51±0.14 -0.15±0.03 2.09E-07 5.85E-05 8.33E-07 
          
 
    
  
CpGs hypermethylated in MPM cases 
      
 
    
 
 
cg08450017 3 45984838 
CXCR6; 
FYCO1 
TSS200 
Body 
0.76±0.11 0.63±0.13 0.13±0.02 1.04E-08 1.26E-05 
 
0.73±0.13 0.63±0.11 0.10±0.02 1.39E-05 9.69E-04 2.31E-05 
cg26033526 6 32819858 TAP1 Body 0.68±0.11 0.56±0.10 0.11±0.02 5.21E-08 2.46E-05  0.67±0.11 0.57±0.09 0.10±0.02 1.46E-06 2.00E-04 3.48E-06 
cg23825480 22 31336785 MORC2 Body 0.78±0.10 0.66±0.10 0.10±0.02 1.28E-08 1.38E-05  0.76±0.11 0.65±0.13 0.10±0.02 2.20E-05 1.34E-03 3.43E-05 
cg00446123 20 62367888 LIME1 TSS200 0.76±0.11 0.64±0.11 0.10±0.02 2.13E-07 5.20E-05  0.73±0.11 0.63±0.11 0.10±0.02 2.64E-06 3.03E-04 5.66E-06 
 
 
Table 3
Table 4: DMRs around DM-CpGs in the Training set and Test set 
 
    
 TRAINING-SET  TEST-SET 
CpG sites in cluster 
Sites 
in 
Cluster 
Map position  
1st CpG in cluster 
(GRCh37/hg19) 
Gene 
Symbol 
UCSC 
Refgene 
Group 
Average Beta-values 
Eff. size±se p p fdr 
 
Average Beta-values 
Eff. size±se p p fdr Cases 
Mean±sd 
Controls 
Mean±sd 
 Cases 
Mean±sd 
Controls 
Mean±sd 
cg26548834; cg04261496; 
cg01509853; cg26177213; 
cg26136772; cg04572930;  
cg15200418; cg18276112; 
cg25344401 
9 Chr7:4752951 FOXK1 Body 0.41±0.18 0.52±0.16 -0.10±0.02 6.90E-11 2.17E-08 
 
0.42±0.18 0.52±0.15 -0.10±0.01 7.24E-12 4.63E-09 
cg26288715; cg27434890; 
cg04739200; cg18835596* 
4 Chr6:135506834 MYB Body 0.39±0.18 0.48±0.16 -0.09±0.02 2.20E-08 7.98E-07 
 
0.31±0.15 0.44±0.16 -0.12±0.02 9.99E-10 7.53E-08 
cg05705212; cg08450017; 
cg25226014; cg01178899 
4 Chr3:45984743 
CXCR6 
FYCO1 
TSS1500 
Body 
0.87±0.10 0.80±0.13 0.06±0.01 6.15E-11 2.02E-08 
 
0.86±0.11 0.80±0.13 0.05±0.01 7.15E-08 1.81E-06 
cg23228341a; cg26033526; 
cg01673307; cg24111025; 
cg02181920; cg06473288; 
cg17626301; cg26234900; 
cg10666909; cg08818207 
10 Chr6:32818477 TAP1 Body 0.79±0.13 0.74±0.13 0.06±0.01 2.50E-08 8.75E-07 
 
0.78±0.13 0.72±0.13 0.06±0.01 2.04E-08 6.85E-07 
cg14977069; cg06653796; 
cg21201401; cg00446123; 
cg20513976; cg24631526; 
cg14396214; cg12413156 
8 Chr20:62367698 LIME1 TSS1500 0.52±0.23 0.45±0.20 0.07±0.01 2.68E-09 1.89E-07 
 
0.49±0.22 0.44±0.20 0.05±0.01 2.47E-05 2.10E-04 
In bold the index CpG (i.e. among the 7 top DM-CpGs) 
In italic underlined CpGs identified also at single-CpGs analysis (i.e. among the 868 DM-CpGs) 
athis CpG is member of the cluster only in Training set 
 
Table 4
Table 5: Correlation between DNA methylation and Gene Expression in the healthy pleura dataset 
Probe ID 
Chromosome 
position 
(GRCh37/hg19) 
UCSC Refgene 
Group 
CpG identified 
in Analysis 
Correlation 
rho 
Correlation 
pa 
Average 
Beta value 
Mean±sd 
Average 
Expr. valueb 
Mean±sd 
       
 
FOXK1c  
cg26548834 Chr7: 4752951 Body Single-CpG/A-clustering  0.50 0.02 0.59±0.10 7.88±0.14 
cg04261496 Chr7: 4753002 Body A-clustering  0.43 0.05 0.50±0.10  
cg01509853 Chr7: 4754502 Body A-clustering  0.51 0.02 0.87±0.04  
cg26177213 Chr7: 4754566 Body Single-CpG/A-clustering  0.43 0.05 0.68±0.10  
cg26136772 Chr7: 4754681 Body A-clustering  0.50 0.02 0.81±0.08  
cg04572930 Chr7: 4754834 Body Single-CpG/A-clustering  0.50 0.02 0.73±0.14  
cg15200418 Chr7: 4755010 Body A-clustering  0.47 0.03 0.56±0.09  
cg18276112 Chr7: 4755032 Body Single-CpG/A-clustering  0.35 0.12 0.56±0.09  
cg25344401 Chr7: 4755415 Body Single-CpG/A-clustering  0.58 0.01 0.75±0.11  
       
 
FYCO1d  
cg08450017 Chr3: 45984838 Body Single-CpG 0.43 0.05 0.81±0.08 8.22±0.20 
 
aIn bold significant p-values (p≤0.05) 
bTranscript level defined as log2 of the fluorescent signal intensity for the BeadChip probe 
cEntrez_Gene_ID 221937, Illumina Probe ID 2082244, RefSeq ID NM_001037165.1, Protein Product NP_001032242.1 
dEntrez_Gene_ID 79443, Illumina Probe ID 1709032, RefSeq ID NM_024513.1, Protein Product NP_078789.1 
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